Your biotech company builds rapid diagnostics. Or environmental biosensors. Or decontamination systems. Or medical countermeasures. COVID proved that these technologies are not just healthcare products. They are critical infrastructure. The EU funds them accordingly.
Why biotech is now a security priority
The pandemic changed how Europe thinks about biological threats. HERA (Health Emergency Preparedness and Response Authority) was created. Biosecurity budgets increased. CBRN (chemical, biological, radiological, nuclear) defence became a top priority. Biotech companies that build detection, protection, and response technologies now sit at the intersection of health and security funding.
The programmes
European Defence Fund: dedicated calls for CBRN detection and decontamination. Rapid pathogen identification, environmental monitoring for biological agents, and medical countermeasures for exposed personnel. 100% funded, up to €5M for SME-led projects.
Horizon Europe Cluster 1 (Health): funds diagnostics, therapeutics, and medical technology R&D. Your clinical diagnostic has a direct path to funding here.
Horizon Europe Cluster 3 (Security): funds civil security applications including CBRN preparedness, critical infrastructure protection, and disaster response technology.
HERA: funds pandemic preparedness technologies including rapid diagnostics, surveillance systems, and medical countermeasures.
EIC Accelerator: funds scaling of biotech products. Now supports dual-use. Good for companies with validated products approaching market.
The dual-use angle
A rapid PCR system designed for hospital labs uses identical technology for field-deployable pathogen detection. A biosensor monitoring water quality does the same job detecting contamination in critical water supplies. Your biotech product already has dual-use applications. The only question is which programme funds the adaptation.
Multiple calls run throughout 2026. Start by mapping which programmes match your technology.
Check if your technology qualifies
Free eligibility check. We analyse your profile against open EU dual-use funding opportunities and get back to you within 48 hours.
Check your eligibility